WOMEN’S MENTAL HEALTH | PREGNANCY AND REPRODUCTIVE PSYCHIATRY
Psychiatric Medication During Pregnancy: How Risk-Benefit Decisions Are Made
The safest plan is not always the plan with the least medication exposure. Thoughtful decisions compare the potential risks of medication with the risks of untreated or undertreated illness, while centering the patient’s history, goals, and values.
By Laura P. McLafferty, MD | Published August 1, 2026
Double Board-Certified in Psychiatry and Consultation-Liaison Psychiatry
“Will this medication harm my baby?”
For many women, pregnancy turns a familiar medication into a source of fear. A treatment that once helped them function may suddenly feel dangerous. Patients may worry that continuing medication is irresponsible, while stopping it may bring back depression, anxiety, panic, obsessive thoughts, insomnia, mania, or other symptoms they worked hard to control.
The uncertainty can become overwhelming. Some women postpone pregnancy planning, stop medication abruptly, or delay prenatal care because they are afraid to disclose that they take psychiatric medication. Others receive conflicting advice from a psychiatrist, obstetrician, primary care clinician, family member, or internet source and feel responsible for making a decision that no one can describe as completely risk-free.
These concerns require careful, nonjudgmental discussion. Psychiatric conditions are medical conditions, and needing treatment during pregnancy is not a failure. The goal is not to eliminate medication exposure at any cost. The goal is to protect both maternal and fetal health through an individualized plan based on the best available evidence and the patient’s clinical history, preferences, and reproductive goals.
The real comparison is not “medication versus no risk”
Every pregnancy involves a background level of risk, and no treatment decision can reduce uncertainty to zero. A medication may carry potential risks, but untreated or undertreated psychiatric illness can also affect the patient, the pregnancy, and the postpartum period. Symptoms may interfere with sleep, nutrition, prenatal care, work, relationships, and the ability to prepare for a newborn. Severe or recurrent illness may also return quickly when an effective treatment is withdrawn.
For this reason, a risk-benefit discussion asks two questions at the same time: What are the known and possible risks of the medication for mother and baby, and what are the likely consequences if the condition is not adequately treated? The answer depends on the medication, diagnosis, severity and recurrence of illness, prior treatment response, stage of pregnancy, medical history, available alternatives, and what matters most to the patient.
Psychiatric medication use during pregnancy is not unusual. In a large U.S. study of more than 1.1 million Medicaid-covered pregnancies, nearly one in twelve involved antidepressant use at some point during pregnancy.
Pregnancy is not, by itself, a reason to stop medication abruptly
One of the most important principles is simple: do not stop psychiatric medication suddenly without speaking with the prescribing clinician. Abrupt discontinuation can cause withdrawal symptoms, sleep disruption, physical discomfort, or a rapid return of the condition or symptoms being treated. For some medications and diagnoses, the potential consequences can be especially serious.
Stopping may ultimately be reasonable for some patients, particularly after careful preconception planning and when illness has been mild, stable, and less likely to recur. For others, continuing an effective medication may offer the best balance of risks and benefits. The decision is not a moral test and should not be made from fear alone.
Past experience is often one of the strongest guides. A patient who previously relapsed after stopping medication, required hospitalization, experienced severe postpartum illness, or needed several treatment trials to become well may face a different risk profile from that of someone with a single mild episode and sustained recovery. In a prospective study of women with recurrent major depression, relapse occurred more often among those who discontinued antidepressant treatment during pregnancy than among those who maintained it. The study does not mean that everyone should continue medication; it simply illustrates why individual history matters.
What a careful medication review considers
A comprehensive consultation is designed to understand both the treatment and the illness it is treating. The review may include:
The current medication, dose, duration of use, effectiveness, side effects, and whether more than one medication is being used.
The diagnosis, current symptoms, severity of prior episodes, age at onset, recurrence pattern, and level of functional impairment.
Previous medication trials, including what helped, what did not help, and what happened during past dose reductions or discontinuation attempts.
Any history of hospitalization, severe depression, mania, psychosis, obsessive-compulsive symptoms, panic, substance use, or postpartum psychiatric illness.
Whether pregnancy is being planned, the current stage of pregnancy, and whether medication exposure has already occurred.
Other medical conditions, pregnancy complications, prescription and over-the-counter medications, supplements, and relevant laboratory findings.
The patient’s priorities, risk tolerance, concerns about fetal exposure, hopes for breastfeeding, and preferences regarding psychotherapy and other supports.
The involvement of an OB/GYN, maternal-fetal medicine specialist, therapist, primary care clinician, or other treating professionals.
Good decision-making is rarely based on a medication label or one research finding. Evidence from pregnancy studies is often observational, and the effects of medication can be difficult to separate from the effects of the underlying illness, other health conditions, smoking or substance use, and differences in access to care. A careful discussion should explain what is known, where uncertainty remains, and how that evidence applies—or may not apply—to the individual patient.
The lowest possible dose is not always the safest dose
Patients often assume that lowering a dose as much as possible must reduce risk. The more useful goal is generally the lowest effective dose: enough treatment to control the condition without unnecessary exposure or side effects. A dose that is too low to prevent symptoms may expose the pregnancy to both medication and inadequately treated illness.
Pregnancy can also change how the body absorbs, distributes, and clears medications. Blood volume, kidney function, liver metabolism, weight, and hormonal changes may alter medication levels over the course of pregnancy. A dose that worked before pregnancy may not have the same effect later. Some patients need no change; others may need adjustment and closer monitoring. Dose decisions should be guided by symptoms, functioning, side effects, and the properties of the specific medication—not by a universal rule to reduce treatment.
Similarly, switching to a medication perceived as “safer” is not automatically safer if the new medication is less effective, causes new side effects, or requires a period of instability while the change is made. A history of good response to the current treatment has clinical value and should be weighed alongside the available reproductive safety data.
Planning before pregnancy helps, but it is never too late to review the plan
Preconception consultation creates time to review the diagnosis, simplify treatment when appropriate, obtain relevant records or laboratory testing, strengthen psychotherapy and practical supports, and develop a relapse-prevention plan before pregnancy begins. It can also reduce the pressure to make major decisions after a positive pregnancy test.
Many pregnancies, however, are unplanned, and many patients seek help only after fetal exposure to medication has already occurred. That does not mean the opportunity for thoughtful care has been lost. A medication should not be stopped reflexively because pregnancy has begun. The treatment plan can be reviewed at any point, and changes can be made deliberately when the expected benefits outweigh the risks of changing course.
Patients should feel able to disclose psychiatric medications to prenatal clinicians without shame. Avoiding prenatal care or withholding information can make coordination more difficult. The purpose of disclosure is not to judge the patient; it is to help the healthcare team plan appropriate monitoring, anticipate medication or postpartum needs, and provide consistent guidance.
A special note about bipolar disorder
Bipolar disorder requires particular caution because pregnancy and the postpartum period can carry a high risk of recurrence, and abrupt discontinuation of mood-stabilizing treatment may substantially increase that risk. In a prospective study of women with bipolar disorder, recurrence of mood episodes during pregnancy was common and occurred sooner and more often among those who discontinued mood stabilizers, especially when discontinuation was rapid. The postpartum period is also a time of heightened vulnerability. Both periods also carry a low but heightened risk of severe mood episodes, including psychosis, if mood-stabilizing medications are discontinued abruptly.
At the same time, medications used for bipolar disorder differ meaningfully in their reproductive risks, monitoring requirements, and effectiveness for a particular patient. This is precisely why broad advice such as “stop all medication” or “continue everything” is unsafe. Patients with bipolar disorder benefit from early planning, accurate diagnosis, coordinated obstetric and psychiatric care, attention to sleep, and a specific postpartum relapse-prevention plan.
What treatment options may be discussed
A consultation does not assume that medication must be continued or discontinued. Depending on the clinical situation, the plan may involve:
Continuing an effective medication when the expected benefits outweigh the potential risks.
Adjusting the dose to maintain effectiveness, reduce side effects, or respond to pregnancy-related changes in medication levels.
Tapering gradually when discontinuation is clinically reasonable and there is a plan for monitoring and rapid response if symptoms return.
Switching medication when there is a compelling safety or effectiveness reason and the transition can be managed carefully.
Reducing unnecessary polypharmacy while preserving the treatment components that are most important for stability.
Starting or continuing psychotherapy, including approaches tailored to depression, anxiety, OCD, trauma-related symptoms, insomnia, or stress.
Strengthening sleep, nutrition, social support, substance avoidance, and other non-medication factors that influence psychiatric stability.
Creating a written relapse-prevention plan that identifies early warning signs, who to contact, and what changes may be needed during pregnancy or after delivery.
Coordinating with the OB/GYN, maternal-fetal medicine specialist, therapist, pediatrician, and other clinicians when appropriate.t.
The best plan may change over time. Pregnancy, delivery, sleep deprivation, breastfeeding, and the transition to caring for a newborn can alter both symptoms and treatment needs. Follow-up allows the plan to remain responsive rather than treating the initial decision as permanent.
Breastfeeding belongs in the same conversation
Breastfeeding questions are often postponed until late pregnancy, but they can influence medication planning much earlier. Medications differ in how much of the mother’s dose passes into breast milk, how well a newborn can clear the medication, and what effects have been reported in nursing infants. The infant’s gestational age, health, feeding pattern, and exposure to other medications may also matter.
For most patients, breastfeeding and psychiatric treatment are not mutually exclusive. Some medications have substantial lactation data; others have limited evidence or require closer infant monitoring. The National Library of Medicine’s LactMed database and MotherToBaby fact sheets provide referenced, medication-specific information that can support—but not replace—clinical decision-making.
The central question remains the same: how can the treatment plan support maternal mental health, infant well-being, feeding goals, and a stable postpartum transition? A patient who becomes severely unwell because effective treatment was withheld may have more difficulty sleeping, bonding, feeding, or caring for herself and her infant. The plan should consider the whole clinical picture rather than treating breastfeeding exposure as the only outcome that matters.
Related care: Postpartum Anxiety and Depression Psychiatry in Philadelphia
You do not have to make these decisions alone
Psychiatric disorders are common during pregnancy, and medication decisions are often complex. There is rarely a perfect answer, but there is usually a thoughtful path forward. Good care compares the risks of untreated or undertreated illness with the potential risks of medication while centering the patient’s treatment goals, values, and preferences.
Planning before pregnancy is ideal when possible, but it is never too late to review and optimize the treatment plan. A comprehensive evaluation can help clarify the diagnosis, identify the factors that make relapse more or less likely, interpret the available evidence, and coordinate a plan across pregnancy, delivery, breastfeeding, and the postpartum period.
The goal is to protect both maternal and fetal health—not to eliminate medication exposure at any cost.
Considering an medical consultation?
Dr. Laura P. McLafferty provides in-person psychiatric consultation and ongoing care in Center City Philadelphia for adults planning pregnancy, currently pregnant, postpartum, or breastfeeding. Treatment decisions are evidence-based, individualized, and coordinated with obstetric and other treating clinicians when appropriate.
About Dr. Laura P. McLafferty
Laura P. McLafferty, MD, is double board-certified in Psychiatry and Consultation-Liaison Psychiatry. Her practice focuses on women’s mental health across the reproductive lifespan, including preconception medication planning, pregnancy and postpartum mental health, PMDD, perimenopause and menopause-related symptoms, and psychiatric concerns occurring alongside complex medical conditions. She completed her psychiatry residency at the University of Pittsburgh Medical Center (UPMC) and her fellowship in Consultation-Liaison Psychiatry at Thomas Jefferson University Hospital.
Educational information only
This article is for general educational purposes and is not individualized medical advice. Reading this article or contacting the practice does not establish a physician-patient relationship. Do not start, stop, taper, switch, or change the dose of a psychiatric medication based solely on information presented here. Medication decisions during pregnancy and breastfeeding should be made with qualified clinicians who can consider the specific medication, diagnosis, medical history, pregnancy, and treatment goals.
Selected sources
American College of Obstetricians and Gynecologists. Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum. ACOG Clinical Practice Guideline No. 5. Obstetrics & Gynecology. 2023;141(6):1262–1288. doi:10.1097/AOG.0000000000005202.
American College of Obstetricians and Gynecologists. Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum. ACOG Clinical Practice Guideline No. 4. Obstetrics & Gynecology. 2023;141(6):1232–1261. doi:10.1097/AOG.0000000000005200.
Viswanathan M, Middleton JC, Stuebe A, et al. Maternal, Fetal, and Child Outcomes of Mental Health Treatments in Women: A Systematic Review of Perinatal Pharmacologic Interventions. Comparative Effectiveness Review No. 236. Agency for Healthcare Research and Quality; 2021.
Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of Major Depression During Pregnancy in Women Who Maintain or Discontinue Antidepressant Treatment. JAMA. 2006;295(5):499–507. doi:10.1001/jama.295.5.499.
Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of Recurrence in Women With Bipolar Disorder During Pregnancy: Prospective Study of Mood Stabilizer Discontinuation. American Journal of Psychiatry. 2007;164(12):1817–1824. doi:10.1176/appi.ajp.2007.06101639.
Huybrechts KF, Palmsten K, Mogun H, et al. National Trends in Antidepressant Medication Treatment Among Publicly Insured Pregnant Women. General Hospital Psychiatry. 2013;35(3):265–271. doi:10.1016/j.genhosppsych.2012.12.010.